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pilepsy is one of the most common and serious
neurological disorders, with up to 60 million people
affected worldwide.
1 Juvenile myoclonic epilepsy (JME)
is a common familial form that accounts for 5–10% of all
epilepsy cases.
2 This form belongs to the idiopathic epilepsy
group, due to the absence of detectable structural or
metabolic abnormalities. Clinically, JME is mainly charac-
terised by isolated myoclonic jerks on awakening that usually
begin during adolescence. It is also highly drug-dependent,
since a 90% recurrence is reported after interruption of
pharmacological treatment.
3
Studies on the incidence of epilepsy in relatives of
probands with JME, as well as on twins, have provided
strong evidence for a genetic contribution.
45 Autosomal
dominant, autosomal recessive, two locus, monogenic, and
polygenic models of inheritance have been suggested.
6 So far,
three genes that are mutated in different forms of JME have
been identified, namely CACNB4,
7 GABRA1,
8 and CLCN2.
9 In
addition, two different susceptibility loci have been identified
by linkage analysis. The first locus, termed EJM1 (OMIM
254770), is on the human leukocyte antigen region of
chromosome 6p.
10 Although no trait-causing mutation has
yet been identified at this locus, association with a haplotype
of the BRD2 gene has been recently reported.
11 The second
locus, termed EJM2 (OMIM 604827), is in the region of
chromosome 15q that contains the gene coding for the a7-
nicotinic acetylcholine receptor subunit. Genetic mapping of
the EJM2 locus defined a 15.1 cM candidate region on
chromosome 15q14, flanked by the D15S165 and D15S971
loci.
6 Interestingly, this region includes the CX36 gene, which
codes for the first connexin identified in neurons.
12
Connexins are integral membrane proteins, encoded by a
family of at least 20 genes in humans, which form the
subunits of gap junction channels.
13 Gap junctions permit the
cell-to-cell passage of ions, second messengers, and small
metabolites and, in the nervous system, provide the
structural basis of electrical synapses.
14 Several studies
indicate the relevance of gap junction-mediated coupling in
maintaining the synchronous activity of neuronal popula-
tions, and the gamma frequency oscillations which are
thought to underlie a range of cognitive processes.
15 16 Thus,
recordings between fast-spiking cells of neocortex has
revealed a high occurrence of electrical coupling,
17 suggesting
that electrical and synaptic coupling act synergistically to
improve neuronal synchronisation.
18 Accordingly, deletion of
CX36 in mice results in loss of electrical synapses, preventing
the synchronous inhibitory activities which underlie gamma
oscillations in the cerebral cortex.
19 20 Further experiments
have revealed that expression of Cx36 is markedly reduced in
the hippocampus of kindled and kainate-treated rats, an
animal model of human temporal epilepsy.
21
These observations, together with the location of the CX36
gene on human chromosome 15q14, make this gene a strong
candidate for JME. To test this hypothesis, we searched for
mutations in the coding regions and intron–exon junctions of
CX36 in most of the European cases of 15q14-linked and in
randomly selected (RS) JME patients. We found that these
patients had no mutation in the coding regions of CX36.
However, several single nucleotide polymorphisms (SNPs)
Abbreviations: CEPH, Centre d’Etude du Polymorphisme Humain; ESE,
exonic splicing enhancer; HW, Hardy-Weinberg; ILAE, International
League Against Epilepsy; JME, juvenile myoclonic epilepsy; LD, linkage
disequilibrium; RS, randomly selected; SNP, single nucleotide
polymorphism
Key points
N Juvenile myoclonic epilepsy (JME) is a generalised form
of epilepsy with onset in early adolescence. Genetic
factors are likely to play a role in the etiology of JME,
and significant evidence supports a major susceptibility
locus located on chromosome 15q14, where the gene
connexin36 (CX36) is also mapped. Since electrotonic
communication between neurons connected by gap
junctions is likely to be implicated in the generation and
maintenance of neuronal synchrony, mutations in the
CX36 gene may be associated with JME.
N Mutation analysis of the human CX36 gene was
undertaken in 29 probands from JME families pre-
viously linked to the 15q14 locus, as well as in 17
randomly selected (RS) JME patients. Sequencing iden-
tified five single nucleotide polymorphisms (SNPs),
c.-127A.T, c.333T.A, c.369C.T, c.588C.T, and
c.888G.A, none of which resulted in an amino acid
substitution.
N A case control study performed on a sample of 29
15q14-linked JME patients, 140 RS JME patients, and
123 controls, demonstrated a significant association
between JME and the c.588C.T polymorphism within
exon 2, with significant differences in both allele
(p=0.03) and genotype (p=0.017) frequencies.
Subjects with the T/T genotype at position 588 had a
significantly increased risk of JME (odds ratio 4.3; 95%
CI 1.49 to 12.3), compared with those with a C/C
genotype. In addition, HAP2, a haplotype containing
c.588C.T, was found to be significantly associated
with JME (p=0.03).
N Further analysis suggested that the c.588C.T poly-
morphism may influence Cx36 gene expression by
affecting exonic splicing enhancers. This defect may
contribute to the pathogenesis of JME.
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cally different from those of controls. Moreover, a haplotype
of CX36 appeared to be over represented in JME patients. The
results provide the first evidence for an association between
CX36 and the 15q14-linked JME families.
METHODS
Cases and control sample
A total of 169 patients with JME were investigated: 29 of
these were unrelated individuals from the families used to
identify the 15q14 susceptibility locus,
6 whereas the other 140
patients were RS from the neurology departments of five
hospitals, irrespective of whether an epileptic syndrome
affected first degree relatives or not.
22 The majority of the
15q14-linked patients (2/3) were clinically ascertained from
within the UK, the others originating from five other
European countries (Denmark, France, Greece, Portugal,
and Sweden). Diagnostic evaluation was made according to
the classification of the International League Against
Epilepsy (ILAE). The control group included unrelated
individuals who were randomly selected from families of
the Centre d’Etude du Polymorphisme Humain (CEPH)
(n=44), and of the Swiss population (n=79). SNP
c.333T.A was further genotyped on 94 additional Swiss
controls. Since allele frequency and distribution of both
genotypes and haplotypes were similar in CEPH and Swiss
controls, these two sub-populations were combined into a
single control group, comprising 123 individuals (50%
women). Informed consent was obtained from all participat-
ing individuals, and the study was approved by the ethic
committees of all participating institutions (National
Hospital for Neurology and Neurosurgery, London; Paris
Hospital Ethics Committee; and Ethical Committee of the
Geneva University Hospital).
Mutation analysis and identification of SNPs
Detection of mutation was performed by genomic PCR
amplification and direct sequencing. We designed primers
using the human genomic sequences (GenBank AC012271)
which encompass CX36. Primer pairs were selected to amplify
fragments covering the whole coding region of this gene, all
intron–exon junctions, and 572 bp of the 59 UTR. Primers
sequences were 59TAAAAGGAAAGGGGGATTCG39 and 59CT
CAGTCCAGGTGTGAGAAGG39 for exon 1; 59CAGCTCCCCA
GTCAAAAGAC39 and 59GGTCACATAAATGAGGGTGGA39 for
exon 2; 59ACGCAGGCGGAGACTACTTA39 and 59CCCGATCA
TAGTGGAGTGCT39 for the 59UTR. Amplification reaction
was performed with 100 ng total genomic DNA. The 25 ml
PCR mixture contained 250 mM deoxynucleotide tripho-
sphates, 200 nM each primer, 2.5 ml1 0 6 PCR buffer
(Finnzymes), and 1.25 U Dynazime Taq polymerase
(Finnzymes, Espoo, Finland). All samples were amplified in
a T Gradient Thermocycler 96 (Biometra, Germany), under
the following conditions: initial denaturation at 94˚ C for
4 min, followed by 35 cycles of denaturation at 94˚ C for 30 s,
annealing at 60˚ C for 40 s, and extension at 72˚ C for 1 min.
After purification, the PCR products were sequenced using
standard protocols, an ABI 377 automated sequencer, and an
additional primer for exon 2 (59CACCAGTCCGCCAAGCAG
CGAG39). Chromatographs of amplicons from affected
individuals were compared to the genomic sequence of the
CX36 gene using the gap4 editor, which is available at the UK
HGMP Resource Centre (http://www.hgmp.mrc.ac.uk). Five
SNPs were characterised and named with reference to the
CX36 cDNA sequence (GenBank NM_020660).
SNP genotyping
Selected regions encompassing each identified SNP were
amplified from genomic CX36 DNA and analysed by
pyrosequencing. The following PCR primer pairs were
employed (b indicates biotin): 59GGTCGGGACGCGCTTGGA
TTT39 and 59bCCCCCTGACCGCCGGCTT39 for c.–127A.T
(expected amplicon 258 bp); 59CCTACTCTGTGCACCAGTC
CG39 and 59bCCCCATTCACAATAGCATTT39 for c.333T.A
and c.369C.T (expected amplicon 174 bp); 59bACTCCACA
CCCATCAGGTCTA39 and 59CGGAACACCACTTGGATAAT39
for c.588C.T (expected amplicon 95 bp); 59bCTCAACCTGG
CTGAACTCAAC39 and 59CCCAGACCTTCATGAAACCTG39 for
c.888G.A (expected amplicon 194 bp). The corresponding
sequencing primers were: 59GATTCGAGGATTTTTT39,5 9GAA
CGCCGCTACTCT39,5 9AGACCCCCCTGAGTC39,5 9GGCAGGA
AGGCATCTC39, and 59CAGGTCCTTGTTACGAAT39, respec-
tively.
All amplification reactions were carried out in a 96 well
microtitre plate thermal cycler (Biometra, Germany), under
the same conditions used for the mutation analysis.
Preparation of single-strand DNA and annealing to the
sequencing oligonucleotide were as reported.
23 Briefly,
attachment of the biotinylated DNA amplicon to streptavi-
din-modified paramagnetic beads was followed by a high salt
washing step, a 10 min NaOH (0.15 M) denaturation step,
and a final annealing step (95˚ C, 15 s). Purified fragments
annealed with the cognate sequencing primers were then
processed for sequencing. DNA mini-sequencing was per-
formed using a PSQ96 instrument, enzymes, and dNTPS (all
from Pyrosequencing AB), as previously described.
23 All the
resulting genotypes, which were automatically assigned to
the samples by the SNP analysis software, were checked by
two independent investigators.
Statistical analysis
The extent of linkage disequilibrium (LD) of each SNP
combination was assessed in all 123 control individuals, by
calculating r
2 using a DNA sequence polymorphism pro-
gram.
24 A two-tailed Fisher’s exact test and the Bonferroni
procedure were computed to determine the significance of
association between polymorphic sites. Five-SNP-locus haplo-
types were inferred from genotypes of the control group,
using the Bayesian method,
25 as provided by PHASE
software. The algorithm deals with missing genotype data,
so that a total of 246 haplotypes were inferred in the control
group. Similarly, haplotypes of both control and JME groups
were inferred for the four SNPs which were selected after LD
analysis, for subsequent case control analysis. CX36 haplotype
genealogies were constructed using the reduced-median-
network approach, available in Network 3.1 software
(Fluxus-engineering; www.fluxus-engineering.com). Hardy-
Weinberg (HW) equilibrium was tested for each SNP using
the HW exact test, as implemented in Genepop software
(http://wbiomed.curtin.edu.au/genepop). Logistic regression
models were used to calculate odds ratios (OR, 95%
confidential interval). The Fisher’s exact test was used for
contingency table inference. To correct for multiple compar-
isons, we used a modified Bonferroni test as described in
Sankoh et al,
26 which accounts for the level of correlation
between linked markers. In this case, p values (0.019 were
taken to indicate a significant difference for a=0.05. For
haplotype associations no correction is required and p values
(0.05 were considered to indicate statistically significant
difference.
RESULTS
CX36 mutation screening
A total of 46 JME patients, including 29 individuals whose
pedigrees had previously been used to determine the 15q14
susceptibility locus, and 17 RS JME patients, were
screened for mutations of CX36, as compared to four
unaffected controls. Screening of the whole coding region,
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of the intron splice-acceptor sites, and 70 bp of the 39-
untranslated region revealed no mutation of the CX36 gene in
JME patients which could result in an amino acid substitu-
tion or affect the splicing and branching sites of RNA.
Polymorphisms
Four SNPs were detected in CX36 exon 2 (table 1). One was a
T.A transversion (c.333T.A), and the three others included
aG .A transition (c.888G.A) and two C.T transitions
(c.369C.T; c.588C.T), respectively. An additional SNP was
identified in the 59-untranslated region (59UTR) of the CX36
and involved an A.T transversion located 127 bp upstream
of the translation initiation codon (c.-127A.T).
Characterisation of SNP genotypes and haplotypes
The allele frequencies of the five CX36 SNPs were determined
in a control group of 123 individuals (table 1). Genotype
frequencies for all SNPs were in HW equilibrium (not
shown). Haplotypic combinations of the five SNPs are shown
in fig 1. A total of eight out of the 32 possible haplotypes were
observed. The most common HAP1 haplotype, which
represents .30% of all haplotypes, was found to be conserved
in non-human primates (fig 1), suggesting that it most likely
represents the ancestral haplotype. To explore the evolution
of the CX36 gene, sequence genealogies were constructed,
using a method that equally weighted all nucleotide
positions. The skeleton network revealed two major branches
in the northern European CX36 genealogy (HAP4 and HAP5
accounting for .30% of all haplotypes, and HAP2 and HAP6
accounting for .25%), which had evolved from a unique
ancestral haplotype (HAP1), via two successive mutations
events (fig 1).
Linkage disequilibrium analysis
Assessing the strength of pairwise linkage disequilibrium
(LD) between the five SNPs of the control population, we
found that SNP369, SNP588, and SNP888 were not in
significant LD (r
2=0.2–0.01) with any other CX36 SNPs
(table 2). In contrast, SNP-127 and SNP333 demonstrated a
highly significant LD with each other (r
2=0.81, p,0.001)
(table 2). These results indicate, first, that CX36 SNPs do not
reside within the same LD block, and, second, that SNP-127
and 333 may be grouped to facilitate association studies,
without loss of statistical power.
Case control study
To determine whether SNP333, 369, 588, and 888 were
associated with JME, we tested 29 unrelated JME patients
that had been shown to have a 15q14 linkage, and 140 RS
JME patients. These two JME groups were analysed both
separately and as a single population. The 15q14-linked JME
sample represents the largest available European set of
patients whose linkage to the 15q14 locus has been
unambiguously established.
62 7Using Fisher’s exact test, we
found that the allele frequency of SNP588 was significantly
(p=0.03) different between the 15q14-linked JME group
and the control group (table 1). We also found a trend
towards a difference (p=0.057) in the allele frequency of
SNP588 between the RS JME group and the control group.
When all the JME patients were pooled and compared to the
control group, the allele frequency of SNP588 was also
significantly different (p=0.03) as judged by the Fisher test,
but did not reach statistical difference when a conservative
correction for multiple testing was applied. This finding
suggests that a small difference in the allele frequency may
become masked because of the rarity of the disease. The risk
of JME increased in the presence of a T allele, in both the
Table 1 Allele frequency of CX36 SNPs in JME cases and controls
SNP* Alleles, n (%) p Value  Function Protein residue Amino acid position dbSNP ID
SNP-129 A T – – – rs2277558
15q14 JME ND ND –
RS JME ND ND –
Combined ND ND –
Control 150 (70.7) 62 (29.3)
SNP333 T A Synonymous Thr 111 rs651724
15q14 JME 44 (75.9) 14 (24.1) 0.29
RS JME 160 (70.2) 68 (29.8) 0.58
Combined 204 (71.3) 82 (28.7) 0.33
Control 292 (67.9) 138 (32.1)
SNP369 C T Synonymous Ser 123 –
15q14 JME 56 (96.50) 2 (3.5) 0.37
RS JME 170 (89.5) 20 (10.5) 0.3
Combined 226 (91.1) 22 (8.9) 0.61
Control 211 (92.5) 17 (7.5)
SNP588 C T Synonymous Ser 196 rs3743123
15q14 JME 34 (58.6) 24 (41.4) 0.033`
RS JME 181 (65.1) 97 (34.9) 0.057
Combined 215 (64) 121 (36) 0.0261
Control 179 (72.8) 67 (27.2)
SNP888 G A Synonymous Glu 296 –
15q14 JME 49 (84.5) 9 (15.5) 0.5
RS JME 229 (88.8) 29 (11.2) 0.88
Combined 278 (88) 38 (12) 1
Control 205 (88.4) 27 (11.6)
ND, Not determined. dbSNP, public database reference (http://www.ncbi.nlm.nih.gov/SNP).
*SNP offset were calculated taking the A of the CX36 start codon as position 1, and using the GenBank accession no. NM_020660;  p Values computed using
Fisher’s exact test, give the significance value of the comparison of SNPs allele frequencies between JME and control cases. Statistically significant associations are
underlined; `OR=1.89; 95% CI 1.03 to 3.45 (odds ratios and their associated 95% CI were calculated for results with p,0.05); 1OR=1.5; 95% CI 1.04 to 2.17.
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(OR=1.89 and 1.5, respectively; table 1).
We then examined the distribution of SNP588 genotypes
(table 3) and found that subjects with a T/T genotype at
position 588 were significantly more numerous in the 15q14-
linked JME group than in the control population (OR=4.3;
95% CI 1.49 to 12.3, p=0.017) as attested by both
uncorrected and corrected tests. In addition the c.588C.T
transition was not in HW equilibrium in the 29 linked cases’
subgroup, due to an over-representation of the T/T genotype
(data not shown).
Haplotype association analysis
To assess whether a combination of multiple SNPs increases
the risk of JME, the frequencies of haplotypes were compared
between cases and controls (table 4). The distribution of
Cx36 haplotypes was significantly different (p=0.02)
between the 15q14-linked JME, and the control group
(table 4). The haplotype TCTG, accounting for .97% of the
Cx36 HAP2 haplotype, was more frequent in the 15q14-
linked JME patients than in controls (0.28 v 0.17), although
the difference failed to reach statistical significance. We
found that homozygous carriers of the HAP2 haplotype had a
significantly increased risk of JME (p=0.03) than either
heterozygous carriers of the HAP2 haplotype (HAP2/X) or
non-carriers (X/X) (table 5). The same increased prevalence
of the HAP2/HAP2 combination was also observed when the
pooled JME group was compared to controls (p=0.04).
Folding of CX36 mRNAs containing synonymous SNPs
To evaluate the effect of the 588T variation, we used the
MFOLD program
28 to predict the structure of the mRNA
coding for CX36. We observed that the predicted structure of
the transcript was similar when the molecule was comprised
of nucleotides 588C, 333A/588C, 369T/588C (fig 2), or -127T/
588C (not shown), which correspond to haplotypes HAP1,
HAP4, HAP7, and HAP5, respectively (fig 1). In contrast, we
found that the presence of allelic variant 588T caused an
obvious change in the predicted structure of the CX36 mRNA,
as illustrated for HAP2 (fig 2). The folding structure of the
three other haplotypes containing the 588T variant (HAP3,
HAP6, and HAP8) were also affected, in a similar way to that
of HAP2 (not shown).
Alteration of potential exonic splicing enhancers by
the 588T nucleotide
To further investigate whether the 588T variation may affect
exonic splicing enhancers (ESEs), we used sequence motif-
scoring matrices predicting consensus functional ESE sites,
29
to analyse exon 2 of wild type (HAP1) and variant (HAP2)
CX36. Multiple high-score binding sites, recognised by the
essential splicing factors SF2/ASF, SC35, SRp40, and SRp55,
Figure 1 The haplotypes of Cx36 SNPs are highly conserved in primates and derived from a common ancestor. European haplotype combinations of
the CX36 gene (HAP1 to HAP8) were inferred by PHASE software in a group of 123 Caucasian control individuals. The corresponding sequences of
the closely related non-human primates are also indicated. Asterisks (*) indicate identity of the human and ape bases. The most common CX36
haplotype (HAP1) is identical in humans and apes and, thus, likely represents the ancestral haplotype. The phylogenetic tree generated by reduced-
median-network analysis, confirmed that all other haplotypes were derived from this ancestral HAP1.
Table 2 Pairwise linkage disequilibrium (r
2) between
CX36 SNPs (unrelated controls)
SNP 333 369 588 888
2127 0.81*** 0.03** 0.14*** 0.05***
333 0.03** 0.18*** 0.06***
369 0.03** 0.01
588 0.32***
Significant pairwise linkage disequilibrium (r
2.0.5) was found between
SNP-127 and 333 (underlined value), but not between the three other
SNPs.
*0.01,p,0.05; **0.001,p,0.01; ***p,0.001.
Table 3 Genotype frequency of SNP588 in JME cases and controls
Group
Genotype at SNP588, n (%)
Total OR (95% CI)* p Value  CC CT TT
15q14 JME 13 (44.8) 8 (27.6) 8 (27.6) 29 4.3 (1.5 to 12.3) 0.017
RS JME 57 (41) 67 (48.2) 15 (10.8) 139 1.37 (0.58 to 3.22) 0.11
Combined 70 (41.7) 75 (44.6) 23 (13.7) 168 1.79 (0.81 to 3.98) 0.09
Control 66 (53.7) 47 (38.2) 10 (8.1) 123
*Odds ratio (OR) compares the T/T genotype to the pool of all other genotypes;  Given by Fisher’s exact test.
Statistically significant associations after Bonferroni correction are underlined.
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588T synonymous nucleotide specifically disrupted the SF2/
ASF motif (CTCCCGC) and the SC35 motif (ATCTCCG),
reducing the cognate score from 2.266 to 0.801 and from
3.176 to 1.441, respectively. The resulting values fell below
the calculated default thresholds for the native motifs (1.95
and 2.38, respectively), indicating that the 588T variation
rendered the SF2/ASF and SC35 ESEs inactive.
DISCUSSION
Juvenile myoclonic epilepsy is a common form of idiopathic,
generalised epilepsy that shows a complex pattern of
inheritance. Two major susceptibility loci, EJM1 on chromo-
some 6p21 and EJM2 on chromosome 15q14, have been
identified by linkage analysis. The finding of a significant
linkage disequilibrium between JME and a haplotype of the
BRD2 gene, which is located on chromosome 6p21, suggested
Table 4 Cx36 haplotype frequency in JME cases and controls
Haplotype* 15q14 JME , n (%) RS JME, n (%) Combined, n (%) Control, n (%)
ACCG 13 (22.4) 81 (28.9) 94 (27.8) 81 (32.9)
TCCG 18 (31.1) 82 (29.3) 100 (29.6) 79 (32.2)
TCTG 16 (27.6) 65 (23.2) 81 (24) 41 (16.7)
TCTA 7 (12.1) 32 (11.4) 39 (11.5) 28 (11.4)
TTCG 1 (1.7) 20 (7.2) 21 (6.2) 16 (6.5)
ACTG 1 (1.7) 0 1 (0.3) 1 (0.3)
TTCA 1 (1.7) 0 1 (0.3) 0
TCCA 1 (1.7) 0 1 (0.3) 0
*Haplotype inferred using PHASE for the four SNPs 333, 369, 588, and 888, respectively; p=0.02 (p value
computed using Fisher’s exact test, gives the significance value of the comparison of haplotype frequencies
between JME and control cases).
Table 5 Association between HAP2 haplotype combinations and JME
Group
Haplotype HAP2, n (%)*
Total OR (95% CI)  p Value` HAP2/HAP2 HAP2/X X/X
15q14 JME 3 (10.5) 10 (34.5) 16 (55) 29 14.8 (1.3 to 147.5) 0.026
RS JME 6 (4) 53 (38) 81 (58) 140 5.46 (0.6 to 48) 0.102
Combined 9 (5.5) 63 (37.5) 96 (57) 168 6.91 (0.8 to 57.6) 0.04
Control 1 (0.8) 39 (31.7) 83 (67.5) 123
*X denotes any haplotype other than HAP2;  OR compare the HAP2/HAP2 combination to all other combinations;
`Given by Fisher’s exact test.
Statistically significant associations are underlined.
Figure 2 The predicted folding structure of Cx36 mRNA is altered by the 588T SNP. A sequence of 1147 bp, covering the complete coding sequence
of Cx36 mRNA and including various synonymous SNPs, was tested with MFOLD software to predict the secondary structure of the transcript. The
folding pattern of HAP1, the most common CX36 haplotype, was not affected by the SNPs we studied (illustrated by HAP4 and HAP7). In contrast, this
structure was markedly altered in haplotypes carrying the 588T SNP, for example in HAP2.
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11 In contrast, the genes involved at the
EJM2 locus are still unknown. In the present study, we
screened the CX36 gene for SNPs and found that the
c.588C.T variant, located in exon 2, is associated with
JME. In addition, we found that the homozygous combina-
tion of HAP2, one of the CX36 haplotypes containing SNP588,
was significantly associated with JME. These findings
suggest that CX36 is a potential susceptibility gene for
juvenile myoclonic epilepsy at the EJM2 locus.
The mechanisms through which SNP588C.T predisposes
to JME remain to be elucidated. First, it is possible that the
c.588C.T transition may be a functional variant of the CX36
gene, conferring susceptibility to JME. This hypothesis is
supported by the finding of a C at position 588 in the
sequence of the ancestral human CX36 haplotype (HAP1), as
well as in the CX36 sequence of non-human primates and
phylogenetically more distant species, such as the house
mouse (GenBank NM_010290.1) and the cow (GenBank
NM_174683.1), indicating an evolutionary conservation of
this base, which suggests a likely importance for the function
of the CX36 gene. In turn, the c.588C.T variant could alter
this function, for example by affecting RNA stability. While
most of the elements which control the stability of mRNAs
are located in the 59- and 39-UTRs of genes, compelling
evidence indicates the presence of other stabilising elements
also in the coding region of many genes.
30 31 Because
individual exons comprise multiple positive and negative cis
elements that affect splicing, some exonic SNPs may
influence splicing efficiency and, therefore, the levels of gene
expression.
32 The predicted changes, both in the secondary
structure of Cx36 mRNA and in two potential ESEs, we
observed for the synonymous SNP588C.T are consistent
with this hypothesis. Further studies, examining the relation
between mRNA stability, exon skipping, translation effi-
ciency, and SNP588 genotype, should determine whether this
variant is indeed responsible for decreased CX36 levels.
Second, it is conceivable that SNP588 may be in linkage
disequilibrium with other variants of the same haplotype that
confer susceptibility to JME. The existence of such variants is
suggested by the association of HAP2, one of the CX36
haplotypes containing SNP588, with JME. The analysis of
haplotype combination showed an over-representation of this
homozygous risk haplotype in the 15q14-linked patients,
consistent with the LOD score maximisation previously
reported at EJM2, using a recessive model.
27 Increasing
evidence indicates that the interaction of multiple SNPs
within a haplotype can lead to functional changes.
31 33 Since
SNPs occur approximately every 500–1000 bp of DNA in
human chromosomes,
34 several other variants are anticipated
in the 59-, 39-UTRs and intron regions of the CX36 gene. The
presence of causative mutations in these regulatory regions
should be further investigated. Third, our data do not exclude
the possibility that the CX36 SNP associated with JME might
be in linkage disequilibrium with variants of another gene,
such as the ACTC gene or another gene located close to CX36.
However, no such gene was identified in the proximity of
CX36, using the UCSC genome browser
35 (not shown).
Recent studies indicate that CX36 is a likely gene for JME.
This gene encodes a protein making channels at electrical
synapses between neurons
12 and at gap junctions between
the electrically excitable insulin-producing b-cells of pan-
creas.
36 In a previous study, we have shown that Cx36-made
channels control the synchronisation of Ca
2+ oscillations in a
transformed cell line.
37 Although no such control has yet been
investigated in neuronal cells, it is consistent with a possible
involvement of Cx36 in the regulation of neuronal excit-
ability. Moreover, it has been shown that the generation of
myoclonic seizures is closely associated with an abnormal
synchronisation of neurons, particularly in the inferior olive,
38
a brain region where Cx36 is highly expressed.
39 In view of
the recent findings that deletion of Cx36 in mice leads to
altered oscillations of interneurons in both hippocampus and
neocortex,
19 20 40 a change in the levels of CX36 could
conceivably be involved in the generation of epileptic
seizures. The lack of such epilepsy events in the Cx36
knock-out model
19 20 40 does not contradict this involvement,
inasmuch as these mice may have developed several
morphological and electrophysiological changes compensat-
ing for the loss of Cx36.
41 These negative findings rather
indicate that the existing murine models may not be relevant
for investigating the participation of Cx36 in complex
diseases, such as human JME. At any rate, this is the first
study which associates a genetic variation in the connexin36
gene with JME.
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